Pre-Filled Syringes & Injectable Drug Devices Europe 2018

SMi Group16 - 17 January 2019, London, UK.
The conference will offer a deep insight into key areas within the field, such as: new technologies and overcoming their hurdles to implementation; connectivity for devices; updates on drug development and the impact on device developments and new regulatory guidelines. The line-up of expert speakers will enable delegates to learn from market leaders on best practices to overcome common industry hurdles.

Join Pre-Filled Syringes & Injectable Drug Devices Europe in January 2019 to network, benchmark and learn about developments at the forefront of the Pre-Filled Syringes and Injectable Drug Devices industry.

Chairs for 2019

  • James Mellman, Device Manager, Novartis
  • Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT

Featured Speakers

  • Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT
  • Cedric Gysel, Staff Device Engineer, Janssen
  • Davide Mercadante, Sr Associate Quality Drug Devices, Biogen
  • Elise Legendre, Head of Late stage PFS Development, Sanofi
  • James Mellman, Device Manager, Novartis
  • Joan Malmstrom, Principal Scientist, Novo Nordisk
  • Justin Wright, Global Head of Innovation, Novartis
  • Maggie Reiff, Associate Device Engineer, Pfizer
  • Mathieu Rigollet, Senior PFS Engineer, Roche
  • Michael Becker, Design Engineer, Boehringer Ingelheim
  • Reinhard Scheller, Commercial ManagerCyclo Olefin Polymers - COP Europe, Zeon Europe GmbH
  • Shota Arakawa, Researcher, Mitsubishi Gas Chemical Company
  • Stephen Barat, Head of Pre-Clinical and Early Clinical Development, SCYNEXIS
  • Steve Chamberlain, Device Engineering Manager, GSK
  • Suraj Ramachandran, Director, Merck
  • Vikas Jaitely, Senior Manager Pharmaceutical Sciences & CMC Regulatory Intelligence, Merck

Key Highlights this January

  • Engage and interact with like-minded individuals through 5+ hours of dedicated networking time, within the conference programme
  • Gain insight from fellow field experts through our interactive programme structure and our fantastic delegation with representation from all aspects of the industry, as well as cross-industry thought leaders and decision makers
  • Discover new technologies being developed to circumvent common industry hurdles and discuss ways in which to overcome the barriers of implementation
  • Hear case studies about the streamlining of injectable device development – from development to market
  • Interact with regulatory bodies in order to glean insight into the most recent revisions to regulation and the best ways to integrate them into business practices
  • Learn about current drug development programmes which will have an imminent impact on the PFS and Injectable devices sector and discuss the influence which drug development has on device development
  • Discuss patient centricity and the impact of human factors on design processes

For further information and to register, please visit:
http://www.pre-filled-syringes.com/wpn

Early-Bird Rates

  • Register by 28th September and save £400
  • Register by 31st October and save £200
  • Register by 30th November and save £100

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

Nucala (mepolizumab) gains FDA approval for two ne…

GlaxoSmithKline (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjec...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Jeff Settleman, Ph.D., joins Pfizer to lead Oncolo…

Pfizer Inc. (NYSE: PFE) announced that Jeff Settleman, Ph.D., will join the company as Senior Vice President and Group Head of Oncology Research & Development, leading al...

Cleveland researchers test novel gene therapy for …

A novel gene therapy clinical trial at University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer Center is showing promising results, garnering funding...

Full data from CAROLINA® outcome trial support lon…

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardio...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Bristol-Myers Squibb announces post-closing leader…

Bristol-Myers Squibb Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with ...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Prescription drug costs steadily soar, yet price t…

After reviewing tens of millions of insurance claims for the country’s 49 most popular brand-name prescription drugs, a team from Scripps Research Translational Institute...